Objective:This study aimed to analyze the temporal trends in cancer mortality in China from 2013-2021 and project the future trends through 2030.Methods:This study was based on the China Causes of Death Surveillance D...Objective:This study aimed to analyze the temporal trends in cancer mortality in China from 2013-2021 and project the future trends through 2030.Methods:This study was based on the China Causes of Death Surveillance Dataset,which covers 2.37 billion person-years.Age-standardized mortality rates(ASMRs)were calculated using Segi’s world standard population and the trends were evaluated via Joinpoint regression.Bayesian age-period-cohort models were used for mortality projections.Contributions of demographic changes(population size and age structure)and risk factors to the mortality burden were quantified using the decomposition analysis.Results:The combined ASMRs for all cancers decreased annually by 2.3%,driven by significant declines in esophageal(4.8%),stomach(4.5%),and liver cancers(2.7%).In contrast,the pancreatic and prostate cancer ASMRs increased by 2.0% and 3.4% annually,respectively.Urban areas demonstrated a more rapid decline in the combined ASMRs for all cancers[average annual percent change(AAPC)=-3.0% in urban areas vs.-2.0% in rural areas],highlighting persistent disparities.Population aging contributed 20%-50% to death increases between 2013 and 2021.The combined ASMRs for all cancers,like the findings of temporal trend analyses,will continue to decrease and the regional(urban and rural)difference is projected to simulate that of the temporal trend through 2030.In fact,cancer deaths are projected to reach 2.4 million by 2030.Conclusions:The cancer burden in China is facing the dual challenges of population aging and urban-rural disparities.It is necessary to prioritize rural screening,control risk factors,such as smoking and diet,and integrate more efficacious cancer prevention and control programmes into the policy to reduce mortality in the future.展开更多
[目的]分析江苏省无锡市2009—2023年居民胃癌死亡变化趋势以及30岁及以上居民年龄、时期、出生队列对胃癌死亡风险的影响。[方法]收集2009—2023年无锡市胃癌死亡资料,计算胃癌的粗死亡率、标化死亡率、寿命损失年(years of life lost,...[目的]分析江苏省无锡市2009—2023年居民胃癌死亡变化趋势以及30岁及以上居民年龄、时期、出生队列对胃癌死亡风险的影响。[方法]收集2009—2023年无锡市胃癌死亡资料,计算胃癌的粗死亡率、标化死亡率、寿命损失年(years of life lost,YLL)、YLL率。使用Join-point回归计算平均年度变化百分比(average annual percentage change,AAPC)分析死亡变化趋势。拟合年龄-时期-队列模型分析30岁及以上人群胃癌死亡风险和死亡负担的年龄、时期及队列效应。[结果]2009—2023年无锡市胃癌共死亡32348例,粗死亡率为44.24/10万,标化死亡率为25.10/10万,YLL共计681618.33人年。胃癌粗死亡率、标化死亡率、YLL率整体均呈下降趋势,AAPC分别为-1.77%(95%CI:-2.10%~-1.43%)、-4.59%(95%CI:-4.97%~-4.20%)和-2.14%(95%CI:-2.56%~-1.74%)。2009—2023年男性胃癌粗死亡率、标化死亡率、YLL均高于女性,但是女性各指标下降速度均快于男性。年龄效应显示,胃癌死亡风险总体随年龄的增长而增加,YLL率随年龄呈先上升后下降的趋势。时期效应显示,随着时间的推移,胃癌死亡风险和死亡负担逐渐下降。队列效应显示,越晚出生的队列胃癌死亡风险和死亡负担越低。[结论]2009—2023年无锡市30岁及以上居民胃癌死亡风险和死亡负担均呈下降趋势。胃癌死亡风险和死亡负担受性别差异和年龄效应影响较大,未来应重点加强中老年男性人群的胃癌筛查和早期干预。展开更多
Objective: Improvement in cancer survival over recent decades has not been accompanied by a narrowing of socioeconomic disparities. This study aimed to quantify the loss of life expectancy(LOLE) resulting from a cance...Objective: Improvement in cancer survival over recent decades has not been accompanied by a narrowing of socioeconomic disparities. This study aimed to quantify the loss of life expectancy(LOLE) resulting from a cancer diagnosis and examine disparities in LOLE based on area-level socioeconomic status(SES).Methods: Data were collected for all people between 50 and 89 years of age who were diagnosed with cancer, registered in the NSW Cancer Registry between 2001 and 2019, and underwent mortality follow-up evaluations until December 2020. Flexible parametric survival models were fitted to estimate the LOLE by gender and area-level SES for 12 common cancers.Results: Of 422,680 people with cancer, 24% and 18% lived in the most and least disadvantaged areas, respectively. Patients from the most disadvantaged areas had a significantly greater average LOLE than patients from the least disadvantaged areas for cancers with high survival rates, including prostate [2.9 years(95% CI: 2.5±3.2 years) vs. 1.6 years(95% CI: 1.3±1.9 years)] and breast cancer [1.6 years(95% CI: 1.4±1.8 years) vs. 1.2 years(95% CI: 1.0±1.4 years)]. The highest average LOLE occurred in males residing in the most disadvantaged areas with pancreatic [16.5 years(95% CI: 16.1±16.8 years) vs. 16.2 years(95% CI: 15.7±16.7 years)] and liver cancer [15.5 years(95% CI: 15.0±16.0 years) vs. 14.7 years(95% CI: 14.0±15.5 years)]. Females residing in the least disadvantaged areas with thyroid cancer [0.9 years(95% CI: 0.4±1.4 years) vs. 0.6 years(95% CI: 0.2±1.0 years)] or melanoma [0.9 years(95% CI: 0.8±1.1 years) vs. 0.7 years(95% CI: 0.5±0.8 years)] had the lowest average LOLE.Conclusions: Patients from the most disadvantaged areas had the highest LOLE with SES-based differences greatest for patients diagnosed with cancer at an early stage or cancers with higher survival rates, suggesting the need to prioritise early detection and reduce treatment-related barriers and survivorship challenges to improve life expectancy.展开更多
Objective This study aimed to investigate the prevalence of Epstein-Barr virus(EBV)infection in patients with and without cancer.Methods A total of 26,648 participants who underwent whole-blood EBV DNA(WBEBV)assays be...Objective This study aimed to investigate the prevalence of Epstein-Barr virus(EBV)infection in patients with and without cancer.Methods A total of 26,648 participants who underwent whole-blood EBV DNA(WBEBV)assays between January 1,2020,and August 31,2023,were included.The chi-square test was used for categorical data analysis,and R software was used to analyze the differences in EBV DNA load levels and the diagnostic capabilities of WBEBV.Results Positive rates were 10.2%and 25.4%for healthy controls(HC)and patients,respectively.The positivity rate for EBV-associated neoplasms(EN)was the highest at 7.53%,followed by leukemia(Le)at 5.49%.The subgroup analysis showed that the positivity rate for abnormal proliferation or hyperplasia(APH)was 31.9%,followed by 30.5%for Le.The WBEBV of patients with transplants(TP),especially living-related transplants(LT),was the highest among all subgroups.WBEBV at diagnosis was used to differentiate between infectious mononucleosis(IM)and chronic active Epstein-Barr virus(CAEBV),with a sensitivity of 67.4%(95%confidence interval[CI]:57.6-75.8)and specificity of 72%(95%CI:63.3-79.3).We conclude that the prevalence of EBV infection is low in the healthy population in this region and that a high EBV load at baseline is more common in LT,IM,and Lymphocyte Leukemia(LL).Conclusion This study used a large-sample survey to characterize the prevalence of whole-blood EBV levels in various diseases,including the stages and subtypes.The EBV detection rate was higher in patients with malignant disease than in those with benign disease.Our study provides clinicians with baseline information regarding EBV-associated diseases.展开更多
目的利用CiteSpace软件和VOSviewer软件梳理中医药治疗化疗相关消化道反应的研究状况、研究热点及趋势,为该领域的未来研究方向提供理论参考。方法计算机检索中国知识资源总库(CNKI)、万方、维普三大中文文献数据库及Web of Science核...目的利用CiteSpace软件和VOSviewer软件梳理中医药治疗化疗相关消化道反应的研究状况、研究热点及趋势,为该领域的未来研究方向提供理论参考。方法计算机检索中国知识资源总库(CNKI)、万方、维普三大中文文献数据库及Web of Science核心合集英文文献数据库、PubMed数据库中有关中医药治疗化疗相关消化道反应的文献,采用CiteSpace 6.3.R1软件分析文献的作者、机构、关键词、聚类及研究热点。结果共纳入分析文献1716篇,2000—2016年发文量平稳上升,自2017年起发文量明显上升;中文作者个人最高发文量为12篇,英文作者最高发文量则为7篇;中文和英文文献发文量以北京中医药大学最多;中文高频关键词主要包括化疗、呕吐等;英文高频关键词主要包括quality of life、cancer等;中文聚类模块较大的为足三里、腹泻、临床疗效等;英文聚类模块较大的为network pharmacology、alternative and complementary medicine等。结论中医药治疗化疗相关消化道反应的中文文献侧重于临床干预效果,英文文献侧重于机制研究。中医非药物疗法如穴位敷贴、针灸和耳穴压丸相关研究是近年来国内研究热点。今后应加强作者之间及不同机构、不同地区之间的合作,以进一步开展相关研究。展开更多
基金supported by the CAMS Innovation Fund for Medical Sciences(Grant No.2021-I2M-1-011)the Capital’s Funds for Health Improvement and Research(Grant No.CFH2024-2G-40214).
文摘Objective:This study aimed to analyze the temporal trends in cancer mortality in China from 2013-2021 and project the future trends through 2030.Methods:This study was based on the China Causes of Death Surveillance Dataset,which covers 2.37 billion person-years.Age-standardized mortality rates(ASMRs)were calculated using Segi’s world standard population and the trends were evaluated via Joinpoint regression.Bayesian age-period-cohort models were used for mortality projections.Contributions of demographic changes(population size and age structure)and risk factors to the mortality burden were quantified using the decomposition analysis.Results:The combined ASMRs for all cancers decreased annually by 2.3%,driven by significant declines in esophageal(4.8%),stomach(4.5%),and liver cancers(2.7%).In contrast,the pancreatic and prostate cancer ASMRs increased by 2.0% and 3.4% annually,respectively.Urban areas demonstrated a more rapid decline in the combined ASMRs for all cancers[average annual percent change(AAPC)=-3.0% in urban areas vs.-2.0% in rural areas],highlighting persistent disparities.Population aging contributed 20%-50% to death increases between 2013 and 2021.The combined ASMRs for all cancers,like the findings of temporal trend analyses,will continue to decrease and the regional(urban and rural)difference is projected to simulate that of the temporal trend through 2030.In fact,cancer deaths are projected to reach 2.4 million by 2030.Conclusions:The cancer burden in China is facing the dual challenges of population aging and urban-rural disparities.It is necessary to prioritize rural screening,control risk factors,such as smoking and diet,and integrate more efficacious cancer prevention and control programmes into the policy to reduce mortality in the future.
文摘[目的]分析江苏省无锡市2009—2023年居民胃癌死亡变化趋势以及30岁及以上居民年龄、时期、出生队列对胃癌死亡风险的影响。[方法]收集2009—2023年无锡市胃癌死亡资料,计算胃癌的粗死亡率、标化死亡率、寿命损失年(years of life lost,YLL)、YLL率。使用Join-point回归计算平均年度变化百分比(average annual percentage change,AAPC)分析死亡变化趋势。拟合年龄-时期-队列模型分析30岁及以上人群胃癌死亡风险和死亡负担的年龄、时期及队列效应。[结果]2009—2023年无锡市胃癌共死亡32348例,粗死亡率为44.24/10万,标化死亡率为25.10/10万,YLL共计681618.33人年。胃癌粗死亡率、标化死亡率、YLL率整体均呈下降趋势,AAPC分别为-1.77%(95%CI:-2.10%~-1.43%)、-4.59%(95%CI:-4.97%~-4.20%)和-2.14%(95%CI:-2.56%~-1.74%)。2009—2023年男性胃癌粗死亡率、标化死亡率、YLL均高于女性,但是女性各指标下降速度均快于男性。年龄效应显示,胃癌死亡风险总体随年龄的增长而增加,YLL率随年龄呈先上升后下降的趋势。时期效应显示,随着时间的推移,胃癌死亡风险和死亡负担逐渐下降。队列效应显示,越晚出生的队列胃癌死亡风险和死亡负担越低。[结论]2009—2023年无锡市30岁及以上居民胃癌死亡风险和死亡负担均呈下降趋势。胃癌死亡风险和死亡负担受性别差异和年龄效应影响较大,未来应重点加强中老年男性人群的胃癌筛查和早期干预。
基金supported by National Health and Research Council of Australia Leadership Investigator Grants (NHMRCAPP1194679)+1 种基金the ACPCC has received equipment and a funding contribution from Roche Molecular Diagnostics USAco-PI on a major implementation programme Elimination of Cervical Cancer in the Western Pacific,which has received support from the Minderoo Foundation。
文摘Objective: Improvement in cancer survival over recent decades has not been accompanied by a narrowing of socioeconomic disparities. This study aimed to quantify the loss of life expectancy(LOLE) resulting from a cancer diagnosis and examine disparities in LOLE based on area-level socioeconomic status(SES).Methods: Data were collected for all people between 50 and 89 years of age who were diagnosed with cancer, registered in the NSW Cancer Registry between 2001 and 2019, and underwent mortality follow-up evaluations until December 2020. Flexible parametric survival models were fitted to estimate the LOLE by gender and area-level SES for 12 common cancers.Results: Of 422,680 people with cancer, 24% and 18% lived in the most and least disadvantaged areas, respectively. Patients from the most disadvantaged areas had a significantly greater average LOLE than patients from the least disadvantaged areas for cancers with high survival rates, including prostate [2.9 years(95% CI: 2.5±3.2 years) vs. 1.6 years(95% CI: 1.3±1.9 years)] and breast cancer [1.6 years(95% CI: 1.4±1.8 years) vs. 1.2 years(95% CI: 1.0±1.4 years)]. The highest average LOLE occurred in males residing in the most disadvantaged areas with pancreatic [16.5 years(95% CI: 16.1±16.8 years) vs. 16.2 years(95% CI: 15.7±16.7 years)] and liver cancer [15.5 years(95% CI: 15.0±16.0 years) vs. 14.7 years(95% CI: 14.0±15.5 years)]. Females residing in the least disadvantaged areas with thyroid cancer [0.9 years(95% CI: 0.4±1.4 years) vs. 0.6 years(95% CI: 0.2±1.0 years)] or melanoma [0.9 years(95% CI: 0.8±1.1 years) vs. 0.7 years(95% CI: 0.5±0.8 years)] had the lowest average LOLE.Conclusions: Patients from the most disadvantaged areas had the highest LOLE with SES-based differences greatest for patients diagnosed with cancer at an early stage or cancers with higher survival rates, suggesting the need to prioritise early detection and reduce treatment-related barriers and survivorship challenges to improve life expectancy.
基金sponsored by Hangzhou Medical Health Science and Technology Project[No.A20220558]the Special Supporting Program of Agriculture and Social Development from Hangzhou Municipal Science&Technology Bureau[No.202203B34].
文摘Objective This study aimed to investigate the prevalence of Epstein-Barr virus(EBV)infection in patients with and without cancer.Methods A total of 26,648 participants who underwent whole-blood EBV DNA(WBEBV)assays between January 1,2020,and August 31,2023,were included.The chi-square test was used for categorical data analysis,and R software was used to analyze the differences in EBV DNA load levels and the diagnostic capabilities of WBEBV.Results Positive rates were 10.2%and 25.4%for healthy controls(HC)and patients,respectively.The positivity rate for EBV-associated neoplasms(EN)was the highest at 7.53%,followed by leukemia(Le)at 5.49%.The subgroup analysis showed that the positivity rate for abnormal proliferation or hyperplasia(APH)was 31.9%,followed by 30.5%for Le.The WBEBV of patients with transplants(TP),especially living-related transplants(LT),was the highest among all subgroups.WBEBV at diagnosis was used to differentiate between infectious mononucleosis(IM)and chronic active Epstein-Barr virus(CAEBV),with a sensitivity of 67.4%(95%confidence interval[CI]:57.6-75.8)and specificity of 72%(95%CI:63.3-79.3).We conclude that the prevalence of EBV infection is low in the healthy population in this region and that a high EBV load at baseline is more common in LT,IM,and Lymphocyte Leukemia(LL).Conclusion This study used a large-sample survey to characterize the prevalence of whole-blood EBV levels in various diseases,including the stages and subtypes.The EBV detection rate was higher in patients with malignant disease than in those with benign disease.Our study provides clinicians with baseline information regarding EBV-associated diseases.
文摘目的利用CiteSpace软件和VOSviewer软件梳理中医药治疗化疗相关消化道反应的研究状况、研究热点及趋势,为该领域的未来研究方向提供理论参考。方法计算机检索中国知识资源总库(CNKI)、万方、维普三大中文文献数据库及Web of Science核心合集英文文献数据库、PubMed数据库中有关中医药治疗化疗相关消化道反应的文献,采用CiteSpace 6.3.R1软件分析文献的作者、机构、关键词、聚类及研究热点。结果共纳入分析文献1716篇,2000—2016年发文量平稳上升,自2017年起发文量明显上升;中文作者个人最高发文量为12篇,英文作者最高发文量则为7篇;中文和英文文献发文量以北京中医药大学最多;中文高频关键词主要包括化疗、呕吐等;英文高频关键词主要包括quality of life、cancer等;中文聚类模块较大的为足三里、腹泻、临床疗效等;英文聚类模块较大的为network pharmacology、alternative and complementary medicine等。结论中医药治疗化疗相关消化道反应的中文文献侧重于临床干预效果,英文文献侧重于机制研究。中医非药物疗法如穴位敷贴、针灸和耳穴压丸相关研究是近年来国内研究热点。今后应加强作者之间及不同机构、不同地区之间的合作,以进一步开展相关研究。
